CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
emapalumab 在抗 CD19 CAR-T 细胞治疗相关细胞因子释放综合征管理中的疗效：2 例病例报告
英文原题：Efficacy of emapalumab in the management of anti‑CD19 chimeric antigen receptor T‑cell therapy‑associated cytokine release syndrome: A report of two cases.
查看英文原题
Efficacy of emapalumab in the management of anti‑CD19 chimeric antigen receptor T‑cell therapy‑associated cytokine release syndrome: A report of two cases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是治疗弥漫性大B细胞淋巴瘤（DLBCL）的有效方法，但可能激活患者全身免疫系统，导致细胞因子释放综合征（CRS）。Emapalumab是一种靶向干扰素γ的人源单克隆抗体，可抑制干扰素γ与细胞表面受体结合及其后续炎症通路激活。本文报告2例复发性DLBCL患者接受CAR-T 细胞治疗后发生严重CRS的病例；使用emapalumab后，CRS得到缓解，同时未损害抗肿瘤疗效。仍需开展前瞻性临床试验，以确定emapalumab在CAR-T 细胞治疗中的作用。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for diffuse large B-cell lymphoma (DLBCL).
However, it may activate the systemic immune system of the patient, resulting in cytokine release syndrome (CRS). Emapalumab is a human monoclonal antibody targeting interferon- , inhibiting its interaction with cell surface receptors and the subsequent activation of inflammatory pathways. The present report describes the cases of 2 patients with relapsed DLBCL treated with CAR T-cell therapy, in which the severe CRS associated with CAR T-cell therapy was attenuated without compromising antitumor efficacy after receiving emapalumab.
Further prospective clinical trials are warranted to determine the role of emapalumab in CAR T-cell therapy.
论文信息
- 作者
- Cai W、Lu Y、He H、Li J、Liu S、Geng H、Yang Q、Zeng L
- 单位
- National Clinical Research Center for Hematological Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.China
- 文献类型
- 病例报告
- 期刊
- Oncology letters2025 Feb
- 原文标识
- PubMed 39628826 · DOI 10.3892/ol.2024.14817
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →